Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 37
GLP-1 drugs cut CV risk in type 2 diabetes
A 2026 network meta-analysis finds GLP-1 therapies reduce mortality and MACE in type 2 diabetes. Semaglutide and albiglutide rank highest.
GLP-1 drugs and hair loss: the data
Hair loss affects roughly 4% of GLP-1 receptor agonist users. The likely cause is rapid weight loss triggering telogen effluvium, not direct follicle damage.
GLP-1 drugs tied to lower heart risk in RA
A TriNetX cohort study found GLP-1 therapy halved heart failure and respiratory failure risk in non-diabetic adults with RA and obesity.
Do GLP-1 drugs reduce fat graft survival?
A scoping review flags several mechanisms through which GLP-1 receptor agonists may reduce fat graft survival. No clinical data exist yet.
Ipamorelin 3x a day: what the evidence says
No human trial has tested a three-times-daily ipamorelin protocol. Here is where the idea comes from and what is missing from the evidence.
IWQOL-Lite-CT: trial vs real-world scores
Real-world adults with obesity score far worse on the IWQOL-Lite-CT than STEP 1 semaglutide trial participants. The instrument works, but baselines differ.
Microdosing tirzepatide: what we know
No trial has tested tirzepatide below 2.5 mg. A 2026 Obesity commentary examines the growing practice of KwikPen microdosing.
Oral semaglutide dropout rates in Japan
A Japanese database study found that high HbA1c and concurrent metformin use predicted early discontinuation of oral semaglutide at the 3 mg starting dose.
"Ozempic Face" Prevention: A New Risk Model
A 2026 paper proposes an anatomy-driven risk model and four-phase prevention algorithm for GLP-1-associated facial aging.
BPC-157 Grey Market Risks and Quality
BPC-157 is sold online with no regulatory oversight. What COA testing can and cannot tell you about identity, purity, and contamination.
PT-141 Grey Market Risks and Quality
Grey-market PT-141 vials lack the controls of FDA-approved Vyleesi. What COA testing reveals about identity, purity, and contamination.
Retatrutide grey market risks
Retatrutide is unapproved and ineligible for compounding. Grey-market vials carry identity, purity, and contamination risks.